B7-H3-向的CAR-Vδ1T细胞表现出强大的宽频活性,对抗固体瘤
Licui Jiang1, Fengtao You2, Hai Wu1
1Cyrus Tang Medical Institute, Collaborative Innovation Center of Hematology, State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, China.
Cancer research
|September 6, 2024
概括
化学抗原受体 (CAR) 修饰的Vδ1T细胞显示出作为固体瘤的现成治疗方法的希望. 一个新的制造工艺使得B7-H3向的CAR-Vδ1T细胞能够有效地消除瘤,并具有良好的安全性.
科学领域:
- 免疫学 免疫学 免疫学
- 细胞疗法细胞疗法
- 在瘤学瘤学.
背景情况:
- Vδ1T细胞是一种罕见的γδT细胞类型,由于其MHC独立的抗原识别,对固体瘤治疗具有前景.
- 隔离和激活Vδ1T细胞的挑战阻碍了它们的临床应用.
- 化学抗原受体 (CAR) 技术提供了一种增强T细胞介导瘤向的方法.
研究的目的:
- 开发一种临床级的Vδ1T细胞制造工艺.
- 评估B7-H3CAR修饰Vδ1T细胞对固体瘤的治疗潜力.
- 在临床前模型中评估这些修饰细胞的疗效和安全性.
主要方法:
- 建立了一个大规模的,临床级的Vδ1T细胞扩张制造协议.
- 工程Vδ1T细胞表达B7-H3特定的CAR和共同表达IL2.
- 测试了B7-H3-CAR-Vδ1T细胞在皮下和正管老鼠异种移植模型中的疗效.
主要成果:
- 开发的过程产生了临床级的Vδ1T细胞.
- 协同表达IL2的B7-H3-CAR-Vδ1T细胞在体外和体内表现出强大而持久的抗瘤活性.
- 单剂量CAR-Vδ1T细胞在多种模型中导致了完整的瘤回归,具有显著的体内扩张和瘤定位.
- 经过修改的细胞表现出良好的安全性.
结论:
- 修改为B7-H3-CAR的Vδ1T细胞是针对固体瘤的可行和有效策略.
- 开发的制造工艺支持CAR-Vδ1T细胞作为"现成"癌症治疗的潜力.
- 这些发现证明了对CAR-Vδ1T细胞治疗固体恶性瘤的进一步临床研究.
更多相关视频
11:08Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
Published on: February 14, 2025
713
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
470
相关概念视频
01:27Tumor Immunotherapy
493
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:27Cytotoxic T Cells-mediated Immune Response
861
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
861
01:30Cancer Vaccines
347
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
347